OVER 581,000 BOTTLES OF BLOOD PRESSURE MEDICATION RECALLED
Teva Pharmaceuticals has voluntarily recalled nearly 581,000 bottles of prazosin hydrochloride capsules, used primarily to treat high blood pressure and prostate conditions and sometimes off-label for PTSD symptoms, after tests detected elevated levels of the potentially cancer-causing impurity N-nitroso prazosin above acceptable limits.
Announced on October 7 and classified by the FDA as a Class II recall on October 24—indicating possible temporary or reversible health effects with low risk of serious consequences—the action affects three strengths distributed nationwide: 181,659 bottles of 1 mg capsules (specific lots expiring October 2025), 291,512 bottles of 2 mg capsules (multiple lots expiring October 2025 to July 2026), and 107,673 bottles of 5 mg capsules (multiple lots expiring into 2026).
Patients are urged to consult their healthcare provider or pharmacist immediately to identify affected lots and explore alternatives, as abrupt discontinuation of blood pressure medication can be risky, while the company continues notifying customers and managing the ongoing recall.
